

CORRECTION

Open Access



Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Michael V. Chiorean¹, Jessica R. Allegretti², Puza P. Sharma³, Benjamin Chastek^{4*}, Leonardo Salese⁵, Elizabeth J. Bell⁴, Jesse Peterson-Brandt⁴, Joseph C. Cappelleri⁶, Xiang Guo⁵ and Nabeel Khan⁷

Correction to: *BMC Gastroenterology* (2022) 22:177

<https://doi.org/10.1186/s12876-022-02215-y>

After publication of this article [1], it was reported that the copyright holder for this article was incorrectly given as “The Author(s)”, but should have been “Pfizer Inc. and The Author(s)”.

The original article [1] has been updated.

Author details

¹Swedish Medical Center, Seattle, WA, USA. ²Brigham and Women’s Hospital, Boston, MA, USA. ³Pfizer Inc, New York, NY, USA. ⁴Optum Life Sciences, HEOR, 11000 Optum Circle, Eden Prairie, MN 55344, USA. ⁵Pfizer Inc, Collegeville, PA, USA. ⁶Pfizer Inc, Groton, CT, USA. ⁷Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Published online: 26 July 2022

The original article can be found online at <https://doi.org/10.1186/s12876-022-02215-y>.

*Correspondence: benjamin.chastek@optum.com

⁴Optum Life Sciences, HEOR, 11000 Optum Circle, Eden Prairie, MN 55344, USA

Full list of author information is available at the end of the article

Reference

1. Chiorean MV, et al. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. *BMC Gastroenterol.* 2022;22:177.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.